Skip to content

Analgesic effect of methylene blue combined with cocktails injected around knee after total knee arthroplasty

Comparative study on the analgesic effect of methylene-blue combined with cocktail and conventional cocktail peri-articular injection after total knee arthroplasty: A prospective, randomized, controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068973
Enrollment
Unknown
Registered
2023-03-02
Start date
2023-03-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

MB group :Methylene blue combine with cocktail
Control group :Conventional cocktail

Sponsors

Affiliated Hospital of Panzhihua University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=50 years, ASA grade I-III; 2. Preoperative diagnosis of knee osteoarthritis; 3. Primary total knee replacement is planned; 4. Informed consent, the patient can independently complete the NRS score and has no mental illness.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to any ingredient in the ‘’cocktail’’ formula; 2. Severe cardiovascular and cerebrovascular diseases and respiratory diseases; 3. Use of opioids before surgery; 4. Patients taking anticoagulant or antiplatelet drugs before surgery; 5. Patients with active peptic ulcer and recent gastrointestinal bleeding; 6. Serious varus or valgus deformity of knee joint; 7. Any central or peripheral neuropathy; 8. Severe renal dysfunction (serum creatinine >200ummol/L); 9. Severe obesity, BMI>35kg/m^2; 10. Patients with hematological diseases, anemia, thrombocytopenia and coagulation disorders; 11. Patients with contraindications of subarachnoid anesthesia puncture.

Design outcomes

Primary

MeasureTime frame
Numerical Rating Scale;The total consumption of sufentanil;

Secondary

MeasureTime frame
IL-6;C-reactive protein, CRP;

Countries

China

Contacts

Public ContactDeng Yijiang

Affiliated Hospital of Panzhihua University

529216819@qq.com+86 189 8034 4155

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026